ClinicalTrials.gov patient consent issues
This article was originally published in The Gray Sheet
Executive Summary
Clinical research stakeholders say a Dec. 29 proposed rule, requiring study sponsors to inform trial participants that information from the study may be submitted to the National Institutes of Health's ClinicalTrials.gov database, should be rewritten to make the required informed consent language more readable. Commenters, including Kaiser Permanente, Johns Hopkins School of Medicine and the Association of Clinical Research Organizations, say the proposed language is far too technical. Several recommend giving sponsors leeway to craft their own ClinicalTrials.gov patient consent language (1"The Gray Sheet" Jan. 4, 2010)
You may also be interested in...
Regulatory News In Brief
Informed consent rule
Regulatory News In Brief
Electro-shock controversy: Psychiatrists and skeptic patient advocacy groups remain split on the safety and efficacy of electroconvulsive shock therapy devices. After requiring manufacturers of certain "pre-amendment" Class III devices, including ECT devices, to submit safety and effectiveness information, FDA opened a docket to allow the public to weigh in as the agency decides whether to require PMAs for the devices or downclassify them (1"The Gray Sheet" Sept. 14, 2009). The psychiatric community maintains that ECT is a safe and effective treatment option for psychiatric disorders such as severe depression. "When patients are appropriately screened and ECT is appropriately delivered, there is no question about its efficacy in a significant percentage of very ill patients," Cleveland Clinic's Donald Malone, M.D., comments. "Requiring a PMA of the current ECT device companies would place a tremendous burden on relatively small companies." Others, such as the Center for Disability Rights, oppose down-regulation. Because of the "severe danger" of electro-shock, the procedure is banned in Texas for children under age 16, noted one psychologist who urged FDA to require PMAs for ECT devices. Though not a booming market, ECT is still used in some facilities; manufacturers include Mecta Corporation (SpECTrum) and Somatics (Thymatron)
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.